Skip to main content
NVDA-2.47%AAPL+1.18%GOOGL-0.43%MSFT-0.18%AMZN-0.04%TSM-2.13%SPCX+1.74%AVGO-0.27%META-0.65%TSLA-0.38%SKHY-5.22%MU-3.82%BRK-B-0.01%LLY+0.41%JPM-0.82%AMD-2.64%WMT+0.89%V-0.32%XOM+0.15%ASMLa-3.01%JNJ0.00%INTC-5.77%MA-0.27%0700.HK-1.94%ORCL-2.65%1398.HK+0.79%BAC-0.41%ABBV+0.61%CSCO-0.30%CVX-0.69%COST+0.22%LRCX-4.40%KO+1.35%CAT-1.64%AMAT-2.69%0005.HK-0.78%AP2d-1.98%UNH+0.66%DELL-3.11%HSBA.L-1.42%MS-0.42%PG+0.02%GE-0.24%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.09%HD-1.23%GS-0.92%0939.HK+1.66%NZDJPY-2.69%AUDJPY-2.02%CHFJPY-1.71%USDJPY-1.50%GBPJPY-1.49%EURJPY-1.44%CADJPY-1.41%EURNZD+1.31%NZDCAD-1.30%NZDUSD-1.23%GBPNZD+1.21%NZDCHF-1.02%USDNOK+0.96%USDZAR+0.88%EURNOK+0.85%CHFNOK+0.80%EURZAR+0.78%NOKJPY-0.73%AUDNZD+0.70%GBPZAR+0.66%USDSEK+0.65%AUDCAD-0.64%AUDDKK-0.62%USDMXN+0.60%EURAUD+0.60%EURSEK+0.54%AUDUSD-0.53%AUDSGD-0.52%GBPAUD+0.51%CHFSEK+0.49%USDTHB+0.49%GBPTRY+0.41%USDPLN+0.34%GBPHKD+0.32%AUDCHF-0.32%NZDSGD-0.29%GBPMXN-0.28%CADCHF+0.28%EURCHF+0.26%EURPLN+0.23%AUDNOK+0.23%USDCHF+0.22%USDSGD+0.21%GBPCHF+0.20%USDILS+0.16%EURHKD-0.13%PLNJPY-0.11%USDDKK+0.11%USDTRY+0.11%GBPCAD-0.10%EURSGD+0.10%NZDMXN+0.08%EURGBP+0.08%USDCAD-0.07%EURUSD+0.06%USDCNH+0.05%CHFSGD+0.04%USDCOP-0.04%EURCNH-0.04%GBPSGD-0.03%SGDJPY+0.03%EURCAD-0.02%EURCZK0.00%USDHKD0.00%EURDKK0.00%GBPUSD0.00%XPTUSD-4.55%HG1-4.30%XAGUSD-4.25%GAGUSD-4.25%UKOIL+2.75%USOIL+2.44%COFFEE-1.86%XAUUSD-0.88%GAUUSD-0.88%W1-0.85%COCOA-0.70%C1-0.42%BTCUSD-1.50%ETHUSD-1.40%USDTUSD-0.05%XRPUSD-2.26%SOLUSD-1.91%TRXUSDT-0.06%ZECUSDT-6.27%DOGEUSD-2.82%XMRUSDT-1.63%LINKUSD-1.27%XLMUSD-1.99%BCHUSDT-9.63%LTCUSD-1.54%UNIUSD-3.92%HBARUSDT-1.68%TONUSD+24.88%SUIUSD-3.17%TAOUSDT-4.43%AAVEUSD-2.97%DOTUSDT-3.07%ICPUSDT-0.65%ONDOUSDT-2.84%WLDUSDT-2.67%ATOMUSDT-3.03%ARBUSDT+1.71%JUPUSDT-2.96%INJUSDT-3.59%STXUSDT-3.43%FETUSDT-2.98%TIAUSDT-1.13%PYTHUSDT-1.00%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-4.89%GRTUSDT-3.13%OPUSDT-3.00%IOTAUSDT-3.54%POLUSDT-6.59%AXSUSDT-2.47%FARTCOINUSDT-2.79%EOSUSDT-1.18%DYDXUSDT-0.88%ORDIUSDT-0.61%GALAUSDT-4.21%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.47%AAPL+1.18%GOOGL-0.43%MSFT-0.18%AMZN-0.04%TSM-2.13%SPCX+1.74%AVGO-0.27%META-0.65%TSLA-0.38%SKHY-5.22%MU-3.82%BRK-B-0.01%LLY+0.41%JPM-0.82%AMD-2.64%WMT+0.89%V-0.32%XOM+0.15%ASMLa-3.01%JNJ0.00%INTC-5.77%MA-0.27%0700.HK-1.94%ORCL-2.65%1398.HK+0.79%BAC-0.41%ABBV+0.61%CSCO-0.30%CVX-0.69%COST+0.22%LRCX-4.40%KO+1.35%CAT-1.64%AMAT-2.69%0005.HK-0.78%AP2d-1.98%UNH+0.66%DELL-3.11%HSBA.L-1.42%MS-0.42%PG+0.02%GE-0.24%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.09%HD-1.23%GS-0.92%0939.HK+1.66%NZDJPY-2.69%AUDJPY-2.02%CHFJPY-1.71%USDJPY-1.50%GBPJPY-1.49%EURJPY-1.44%CADJPY-1.41%EURNZD+1.31%NZDCAD-1.30%NZDUSD-1.23%GBPNZD+1.21%NZDCHF-1.02%USDNOK+0.96%USDZAR+0.88%EURNOK+0.85%CHFNOK+0.80%EURZAR+0.78%NOKJPY-0.73%AUDNZD+0.70%GBPZAR+0.66%USDSEK+0.65%AUDCAD-0.64%AUDDKK-0.62%USDMXN+0.60%EURAUD+0.60%EURSEK+0.54%AUDUSD-0.53%AUDSGD-0.52%GBPAUD+0.51%CHFSEK+0.49%USDTHB+0.49%GBPTRY+0.41%USDPLN+0.34%GBPHKD+0.32%AUDCHF-0.32%NZDSGD-0.29%GBPMXN-0.28%CADCHF+0.28%EURCHF+0.26%EURPLN+0.23%AUDNOK+0.23%USDCHF+0.22%USDSGD+0.21%GBPCHF+0.20%USDILS+0.16%EURHKD-0.13%PLNJPY-0.11%USDDKK+0.11%USDTRY+0.11%GBPCAD-0.10%EURSGD+0.10%NZDMXN+0.08%EURGBP+0.08%USDCAD-0.07%EURUSD+0.06%USDCNH+0.05%CHFSGD+0.04%USDCOP-0.04%EURCNH-0.04%GBPSGD-0.03%SGDJPY+0.03%EURCAD-0.02%EURCZK0.00%USDHKD0.00%EURDKK0.00%GBPUSD0.00%XPTUSD-4.55%HG1-4.30%XAGUSD-4.25%GAGUSD-4.25%UKOIL+2.75%USOIL+2.44%COFFEE-1.86%XAUUSD-0.88%GAUUSD-0.88%W1-0.85%COCOA-0.70%C1-0.42%BTCUSD-1.50%ETHUSD-1.40%USDTUSD-0.05%XRPUSD-2.26%SOLUSD-1.91%TRXUSDT-0.06%ZECUSDT-6.27%DOGEUSD-2.82%XMRUSDT-1.63%LINKUSD-1.27%XLMUSD-1.99%BCHUSDT-9.63%LTCUSD-1.54%UNIUSD-3.92%HBARUSDT-1.68%TONUSD+24.88%SUIUSD-3.17%TAOUSDT-4.43%AAVEUSD-2.97%DOTUSDT-3.07%ICPUSDT-0.65%ONDOUSDT-2.84%WLDUSDT-2.67%ATOMUSDT-3.03%ARBUSDT+1.71%JUPUSDT-2.96%INJUSDT-3.59%STXUSDT-3.43%FETUSDT-2.98%TIAUSDT-1.13%PYTHUSDT-1.00%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-4.89%GRTUSDT-3.13%OPUSDT-3.00%IOTAUSDT-3.54%POLUSDT-6.59%AXSUSDT-2.47%FARTCOINUSDT-2.79%EOSUSDT-1.18%DYDXUSDT-0.88%ORDIUSDT-0.61%GALAUSDT-4.21%NOTUSDT-2.97%RONINUSDT-2.64%
KO

Kura Oncology, Inc. (KURA)

NASDAQ • Healthcare

$12.09
-$0.42 (-3.4%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$12.5
Previous Close$12.09
Day Range$11.99 - $12.61
Avg. Volume (3M)2.4M
Market Cap$1B
52 Week Range
$7.36$13.9
Next EarningsIn 54 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$20.8M100%
Gross Profitminus cost of goods$20.6M99%

Fundamentals & Financials

Revenue (TTM)
$77.2M
Net Income (TTM)
-$296.7M
EPS (TTM)
-$3.37
ROA (TTM)
-50.49%
Current Ratio
4.73

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-27.8%Q1 2026-$0.92
+5.7%Q2 2026-$0.83
+12.2%Q3 2026-$0.77
Next

Nov 3

in 54 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +12.2%

Kura Oncology topped consensus on both the top and bottom line in the second fiscal quarter of 2026 (period ended June 30, 2026, reported August 12, 2026), with EPS of -$0.77 topping the -$0.88 estimate by $0.11 and revenue of $20.9 million topping the $20.2 million estimate (+3.5%). Revenue rose 37% to roughly $20.9 million, up from about $15.3 million a year ago, as the company continued to generate revenue alongside its oncology pipeline work in programs such as KOMZIFTI and other targeted candidates. Gross profit came in at around $20.6 million, with gross margin near 99%, while operating income was -about $73.0 million. Net income was negative roughly $68.3 million, down 3% from about -$66.1 million a year ago, and the -$0.77 EPS compared with -$0.75 a year ago. For the next period, consensus calls for EPS of -$0.84 on revenue of $23.8 million.

View full earnings history

About Kura Oncology, Inc.

Kura Oncology, Inc. (NASDAQ: KURA) is a biotechnology company that develops medicines for the treatment of cancer. In FY2025, it generated $67.5 million in revenue. The company centers its current portfolio on targeted drug candidates including KOMZIFTI, a menin inhibitor, alongside Darlifarnib and KO-7246.

Name
Kura Oncology, Inc.
CEO
Troy Wilson
Website
kuraoncology.com
Industry
Healthcare
Employees
260

Today's Snapshot

AI-generated

Yesterday KURA fell 3.4% to 12.09. Kura Oncology launched Caspian Therapeutics, a diabetes-focused subsidiary, with $50 million to advance menin-inhibitor research.

Trading Volume

Above 10d avg 1.9M

2.2M

vs S&P 500 Today

Underperforming Market

-2.95%

Updated: September 10, 2026 at 12:10 UTC

Technical Indicators

3 Buy3 Neutral2 Sell
KURA posts a buy score while trading near 12.09, supported by a firm trend and constructive volume. ADX around 34 indicates strong directional strength, and OBV signals accumulation, while momentum measures are largely neutral with MACD slightly positive and RSI around the mid-50s. The price is below the short 10–20 day averages but sits comfortably above the 50/100/200-day lines, and ATR is elevated, reflecting higher relative volatility. The pivot is above the market. Technical takeaway: strong trend readings and positive volume profile favor a buy bias despite short-term mean reversion signals.
All signals
  • EMA (5 indicators)$10.15 - $12.63
    Buy
  • RSI (14)51.69
    Neutral
  • Stochastic %K (14, 3, 3)48.18
    Neutral
  • MACD Level (12, 26)0.59
    Neutral

Peers & Related Assets

TNGXTango Therapeutics, Inc.
$24+5.7%
MRVIMaravai LifeSciences Holdings, Inc.
$6.95-3.3%
BCAXBicara Therapeutics Inc. Common Stock
$23.64-0.3%
TYRATyra Biosciences, Inc.
$22.01-17.7%
REPLReplimune Group, Inc.
$14.45-2.2%
SVRASavara Inc.
$5.42-2.0%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.